A single-center, prospective study on the susceptibility to adverse reactions of voriconazole in patients with hematological malignancy

Study on the interaction mechanism between statins and triazole antifungal agents and the dose adjustment model of combined administration

Status

Recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2100043331

Enrollment

Unknown

Registered

2021-02-10

Start date

2021-03-01

Completion date

Unknown

Last updated

2021-06-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hematological malignant tumor disease

Interventions

HM Group:Nil

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Aged >= 18 years; 2. Receiving intravenous voriconazole (Vfend) for prevention or treatment of invasive fungal infections.

Exclusion criteria

Exclusion criteria: 1. Absence of voriconazole plasma concentration; 2. Incomplete important dosing information or clinical data.

Design outcomes

Primary

Measure	Time frame
Voriconazole plasma concentration;	—

Countries

China

Contacts

Public ContactXixiao Yang

Shenzhen Hospital, Southern Medical University

yxixiao@163.com+86 13926034745

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026